
GLP1s and rare side effect that causes blindness
Notes de l’épisode
In the news:
In the United States, the FDA will now require GLP1 medications to carry package warnings about a rare side effect that causes blindness. The TGA made a similar change here a few months ago, but what is NAION and what do you need to know about it?
More results are published for drugs that were created to reduce LP(a), a cholesterol that is a precursor to heart disease and stroke risk, and the results are again not what was hoped. Where to from here?
Catholic health care provider Calvary Health's purchase of two NSW Hunter region hospitals means some services will no longer be available, including IVF and other assisted reproductive technologies, voluntary assisted dying, elective terminations of pregnancy, and gender reassignment procedures.
References
- FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition
- TGA Medicine Safety Update: GLP-1 RAs and rare vision disorder
- Health Report: Heart disease prevention drug fails at final hurdle
- Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease
- Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)
- Calvary Health Care purchase of Newcastle Private Hospital and Hunter Valley Private Hospital
Tous les épisodes de Health Report – Separate stories podcast